Second Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Acute Lymphoblastic Leukemia (ALL) — an Option to Consider

R. Duerst(Northwestern University), Morris Kletzel(Lurie Children's Hospital), Jennifer Schneiderman(Northwestern University), David A. Jacobsohn(Children's National), Sonali Chaudhury(Northwestern University), William Tse(Lurie Children's Hospital)
Transplantation and Cellular Therapy
January 23, 2009
10.1016/j.bbmt.2008.12.250
Cited by 0

Related Papers

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
|Biology of Blood and Marrow Transplantation|2014|442
Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD
|Journal of Clinical Oncology|2021|255
Allogeneic Human Mesenchymal Stem Cell Therapy (Remestemcel-L, Prochymal) as a Rescue Agent for Severe Refractory Acute Graft-versus-Host Disease in Pediatric Patients
|Transplantation and Cellular Therapy|2013|248
Unrelated Donor Cord Blood Transplantation for Children with Severe Sickle Cell Disease: Results of One Cohort from the Phase II Study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)
|Transplantation and Cellular Therapy|2012|201